treatment modalities of Graves’ hyperthyroidism (GH). Systemic glucocorticoids (GCs) were commonly employed in active GO since the 1950s. Over the past decade, we have witnessed the emergence of novel therapeutics which better target the immunological
Alan Chun Hong Lee and George J. Kahaly
Meihua Jin, Ahreum Jang, Chae A Kim, Tae Young Kim, Won Bae Kim, Young Kee Shong, Min Ji Jeon, and Won Gu Kim
Introduction Graves’ hyperthyroidism is an autoimmune disease in which thyrotropin (thyroid-stimulating hormone (TSH)) receptor antibody (TRAb) stimulates thyroid follicular cells, resulting in thyrotoxicosis and enlargement of the thyroid
George J. Kahaly, Luigi Bartalena, Lazlo Hegedüs, Laurence Leenhardt, Kris Poppe, and Simon H. Pearce
with suspected Graves’ hyperthyroidism. TSH-R-Ab are specific biomarkers for GD [ 2 , 22 ]. Most immunoassays today use a competitive-binding assay and measure what are referred to as TSH-R binding inhibitory immunoglobulins (TBII). Binding
J Karmisholt, S L Andersen, I Bulow-Pedersen, A Krejbjerg, B Nygaard, and A Carlé
Introduction Graves’ hyperthyroidism (GH) is an autoimmune disease mainly affecting the thyroid gland ( 1 , 2 ). The disease is usually transient with remission occurring within a period of 1–2 years after treatment with anti-thyroid drugs
Earn H. Gan, Anna L. Mitchell, Ruth Plummer, Simon Pearce, and Petros Perros
by thyroid disorders. This report describes a case of Graves hyperthyroidism after 8 years of tremelimumab therapy. We speculate a causal relationship between tremelimumab therapy and the development of Graves disease, and highlight the importance
Tetsuya Mizokami, Katsuhiko Hamada, Tetsushi Maruta, Kiichiro Higashi, and Junichi Tajiri
What Is Known about This Topic? • Anterior neck pain and fever, caused by radiation thyroiditis, is a rare occurrence after 131 I therapy for Graves' hyperthyroidism. In addition, the ultrasonographic findings have not been well described
Elena Sabini, Ilaria Ionni, Roberto Rocchi, Paolo Vitti, Claudio Marcocci, and Michele Marinò
deterioration of Graves’ orbitopathy in patients with Graves’ hyperthyroidism. A similar release of autoantigens may occur at the eye level resulting in the development of Graves’ orbitopathy. What Does This Case Report Add? To our knowledge
Allan Carlé, Nils Knudsen, Torben Jørgensen, Bettina Thuesen, Jesper Karmisholt, Stine Linding Andersen, and Inge Bülow Pedersen
studies [ 5 ], have shown a lower risk during pregnancy of developing autoimmune thyroid disease such as Graves’ hyperthyroidism and autoimmune hypothyroidism. Due to the so called “rebound phenomenon,” the risk of autoimmune thyroid disease after delivery
Mahdi Kamoun, Michèle d'Herbomez, Christine Lemaire, Armelle Fayard, Rachel Desailloud, Damien Huglo, and Jean-Louis Wemeau
Background: Coexistence of thyroid-stimulating hormone (TSH)-secreting pituitary adenoma (TSHoma) with Graves' disease has been rarely reported. We describe a female patient displaying TSHoma with Graves' disease and who presented initially with inappropriate TSH values. Case Report: A 36-year-old woman presented with signs of thyrotoxicosis, small and vascular goiter and mild bilateral exophthalmos. Thyroid function tests showed hyperthyroxinemia and normal TSH values despite the use of different assays. Heterophile antibody testing result was negative. The patient underwent total right lobectomy with partial left lobectomy after 18 months of carbimazole treatment. Histology confirmed Graves' disease. Symptoms of thyrotoxicosis recurred 2 months later. Thyroid function tests showed hyperthyroxinemia and elevated TSH values. Investigations were consistent with a 10-mm TSHoma. The patient underwent a trans-sphenoidal tumor resection following preoperative lanreotide preparation. Histological examination and immunocytochemistry concluded to a pure TSH-producing tumor. There was no evidence of tumor recurrence after 18 years of follow-up. Conclusion: Association of TSHoma with Graves' disease should be carefully taken into account, especially when TSH values are not compatible with either the clinical history or other thyroid functions tests.
Roberto Negro, Laszlo Hegedüs, Roberto Attanasio, Enrico Papini, and Kristian H. Winther
. 2017 Oct ; 24 ( 5 ): 348 – 55 . 10.1097/MED.0000000000000356 28639965 1752-296X 19 Kahaly GJ , Riedl M , König J , Diana T , Schomburg L . Double-Blind, Placebo-Controlled, Randomized Trial of Selenium in Graves Hyperthyroidism
